2015 BioPacific Conference Agenda

Theme: Opportunities, Challenges, and Growth – A New Era in Biomedical Innovation

May 9th, Saturday, 2015, San Mateo Marriott, 1770 South Amphlett Blvd., San Mateo, CA 94402

The official working language of the conference is English

8:00 – 9:00 am Registration and Vendor Exhibition
9:00 – 9:05 am Opening Remarks
Jiangwen Majeti, Ph.D./MBA, CABS President-elect & 2015 BioPacific Conference Organizing Committee Chair
9:05 – 9:15 am State of the Society
Alan Hao, Ph.D., CABS President
9:15 – 10:05 am CABS K. Fong Award in Life Sciences & Keynote Speech

Award Winner: Dr. Irv Weissman
Irv Weissman, Ph.D., Virginia & D. K. Ludwig Professor, Stanford University
Normal and Neoplastic Stem Cells

10:05 – 12:20 pm Developing Novel Therapies through Discovery and Technology Innovation
Session chairpersons: Shichang Miao
10:05 – 10:40 am Allen Ebens, Ph.D., Senior Director of Research, Juno Therapeutics
Adoptive Cell Therapies for Cancer: Challenges and Opportunities
10:40 – 11:10 am Coffee Break, Vendor Exhibition & Networking
11:10 – 11:45 am Jerry Shen, Ph.D., Executive Director of Biology, BioMarin Pharmaceutical Inc.
BioMarin, a SF/Bay Area Growth Story
11:45 am – 12:20 pm Peter Staehr, Ph.D., Senior Director, Global Trials, Abbott Vascular
Development of a coronary bioresorbable scaffold – The next revolution in Interventional Cardiology
12:20 pm – 12:40 pm Thomas Irving, J.D., Partner, Finnegan
Developing U.S. Patents for Novel Therapies Through Discovery and Technology Innovations
12:40 – 1:30 pm Lunch
1:30 – 2:50 pm Celebrating Bay Area Biotech Industry Organic Growth
Session chairpersons: Jiwen Liu
1:30 – 2:00 pm Jin-long Chen, Ph.D., Founder & Chief Scientific Officer, NGM Biopharmaceuticals, Inc.
Building an “Old School” Biotech Company to Discover Novel Biological Medicines
2:00 – 2:30 pm Aaron Sato, Ph.D., Vice President of R&D, Sutro Biopharma
Sutro Biopharma: A Bay Area Biotech Veteran that Reinvented Itself
2:30 – 2:50 pm Stephen Thau, JD, Partner, Morrison & Foerster LLP
Status update for deals and financings in biotechnology
2:50 – 3:15 pm Platinum and Gold Sponsor Presentations
3:15 – 3:45 am Coffee Break, Vendor Exhibition & Networking
3:45 – 5:00 pm US/China Biomedical Science Funding Trend
Session chairpersons: Howard Huang
3:45 – 4:10 pm Ming Zhao, Ph.D., Senior Director, SBIR Development Center, NCI
NCI SBIR&STTR: Advancing the Commercialization of New Cancer Innovation
4:10 – 4:35 pm Darren Ji, Ph.D., Global Head/Vice President, Asia and Emerging Markets Partnering, F. Hoffmann-La Roche
Maximizing the Capital Efficiency for Drug R&D through Creative Partnerships
4:35 – 5:00 pm Jimmy Z. Zhang, Ph.D./MBA, Vice President, Transactions, J&J Innovation, Asia Pacific.
New Ways to Source and Fund Innovations
5:00 – 5:30 pm Platinum and Gold Sponsor Presentations
5:30 – 6:00 pm Happy Hour
6:00 – 7:00 pm Dinner
7:00 – 8:30 pm New Therapeutic Development in China
Session chairpersons: Tao Huang and Cheni Kwok
7:00 − 7:20 pm Chengbin Wu, Ph.D., Chief Scientific Officer and President, Shanghai CP Guojian Pharmaceuticals Co., Ltd.
Developing Therapeutic Antibodies in China: Biosimilars and Beyond
7:20 − 7:40 pm Dechao Yu, Ph.D.,President and CEO, Innovent Biologics, Inc.
Innovative Biologics in China: Challenges and Opportunities
7:40 − 8:00 pm Weidong Jiang, Ph.D., CSO&VP, Henlius Biopharmaceuticals Inc.
Antibody therapeutics in China: a challenging pathway
8:00 − 8:20 pm Lan Huang, Ph.D., Co-Founder & CEO, BeyondSpring Pharmaceuticals, Inc.
New US-China Integration Model for Innovative Drug Development for the Global Market
7:50 – 8:30 pm Group Q & A
8:30 pm Conference Adjourned